Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and safety of risankizumab, a humanized immunoglobulin G1 mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimball, Alexa B., Prens, Errol P., Passeron, Thierry, Maverakis, Emanual, Turchin, Irina, Beeck, Stefan, Drogaris, Leonidas, Geng, Ziqian, Zhan, Tianyu, Messina, Izabella, Bechara, Falk G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997424/
https://www.ncbi.nlm.nih.gov/pubmed/36892753
http://dx.doi.org/10.1007/s13555-023-00913-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997424/
https://www.ncbi.nlm.nih.gov/pubmed/36892753
http://dx.doi.org/10.1007/s13555-023-00913-3

Ejemplares similares